2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.29: Clinical and Economic Impact of the Availability of Innovative Therapies for Advanced Lung Cancer in Latin America

PP01.29: Clinical and Economic Impact of the Availability of Innovative Therapies for Advanced Lung Cancer in Latin America

Back to course

Pdf Summary

The study investigates the clinical and economic impacts of innovative therapies for advanced lung cancer in five Latin American countries: Argentina, Brazil, Chile, Colombia, and Mexico. Over 184 new cancer therapies emerged worldwide between 2002 and 2012, significantly reducing cancer-related mortality. However, in Latin America, the average availability time of these treatments can be extended, affecting patient outcomes due to delayed local approvals.<br /><br />The research identified 24 FDA-approved therapies for advanced lung cancer available between 2006 and 2021 across the evaluated countries. By 2021, Argentina had 70% of these therapies available, Brazil 73%, Chile 77%, Colombia 60%, and Mexico 67%. Delays in therapy availability are linked to significant economic impacts, such as productivity losses and years of life lost due to early mortality.<br /><br />The study estimated that, between 2006 and 2021, 8,694 deaths could have been avoided across the five countries if innovative treatments had been available without delay. These delays potentially resulted in 114,477 years of life lost, mostly among the productive age population (ages 40-64), translating into a productivity loss of USD 439 million. Brazil and Argentina experienced the highest productivity losses due to their large populations and Argentina’s high GDP per capita.<br /><br />The analysis emphasizes the potential benefits of improving regulatory processes to accelerate access to these therapies in Latin America. Faster approval and availability could improve survival rates and economic growth by preventing productivity losses due to premature cancer-related mortality. Overall, the research encourages reforms in regulatory processes to enhance access and optimize outcomes for lung cancer patients, highlighting a need to balance clinical innovations with swift policy adaptations.

Asset Subtitle

Andres Cardona

Keywords

innovative therapies

advanced lung cancer

Latin America

Argentina

Brazil

Chile

Colombia

Mexico

regulatory processes

economic impacts